Uncertainty about the risks of medications for IBD during pregnancy is a challenge for clinicians and patients. A recent prospective cohort study suggests that women under medical care for their disease have few adverse events.
This is a preview of subscription content, log in via an institution to check access.
References
Baiocco, P. J. & Korelitz, B. I. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J. Clin. Gastroenterol. 6, 211–216 (1984).
Bush, M. C., Patel, S., Lapinski, R. H. & Stone, J. L. Perinatal outcomes in inflammatory bowel disease. J. Matern. Fetal Neonatal Med. 15, 237–241 (2004).
Hawthorne, A. B. et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305, 20–22 (1992).
Candy, S. et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37, 674–678 (1995).
Coelho, J. et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60, 198–203 (2011).
De Vigan, C. et al. Prevalence and prenatal diagnosis of congenital malformations in the Parisian population: twenty years of surveillance by the Paris Registry of congenital malformations [French]. J. Gynecol. Obstet. Biol. Reprod. (Paris) 34, 8–16 (2005).
Dominitz, J. A., Young, J. C. & Boyko, E. J. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am. J. Gastroenterol. 97, 641–648 (2002).
Nguyen, G. C., Boudreau, H., Harris, M. L. & Maxwell, C. V. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin. Gastroenterol. Hepatol. 7, 329–334 (2009).
Gould, S. R., Brash, A. R., Conolly, M. E. & Lennard-Jones, J. E. Studies of prostaglandins and sulphasalazine in ulcerative colitis. Prostaglandins Med. 6, 165–182 (1981).
Reddy, D., Murphy, S. J., Kane, S. V., Present, D. H. & Kornbluth, A. A. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am. J. Gastroenterol. 103, 1203–1209 (2008).
Mahadevan, U. et al. A multi-center national prospective study of pregnancy and neonatal outcomes in women with inflammatory bowel disease exposed to immunomodulators and biologic therapy [abstract]. Gastroenterology 136 (Suppl. 1), A-88 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Levesque, B., Kane, S. Measuring what counts—safety of IBD medications in pregnancy. Nat Rev Gastroenterol Hepatol 8, 126–128 (2011). https://doi.org/10.1038/nrgastro.2011.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.18
- Springer Nature Limited